Pharma · Private company
Servier Bio-Innovation LLC
Track this companyFree. Adds Servier Bio-Innovation LLC to your Dealase workspace and tells you when its record changes.
Clinical trials106 recruiting or active
Pipeline programs21From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline21
- Ivosidenib 500mgPhase 3 · Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment RegimenClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · IDH1-mutant CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- IvosidenibPhase 2 · IDH1-mutant CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · IDH1-mutant CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab 200 mg (KEYTRUDA ®)Phase 2 · MSI-H/dMMR Gastroesophageal-junction CancerClinicalTrials.gov · fetched Nov 12, 2026
- PRS-344/S095012Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- S095018Phase 2 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- S095018 Recommended Dose Expansion (RDE)Phase 2 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- S095024Phase 2 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- S095024 RDEPhase 2 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- S095029Phase 2 · MSI-H/dMMR Gastroesophageal-junction CancerClinicalTrials.gov · fetched Nov 12, 2026
- S095029Phase 2 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- S095029 RDEPhase 2 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- S095035Phase 2 · MTAP-deleted Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- S227928Phase 2 · Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- TNG462Phase 2 · MTAP-deleted Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- Ciprofloxacin 500 mg Oral TabletPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Ivosidenib Oral TabletPhase 1 · IDH1-Mutated MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- Vorasidenib 10 mg Oral TabletPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Vorasidenib 40 mg Oral TabletPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentPHASE1 · RECRUITING · started Jan 14, 2026ClinicalTrials.gov NCT07006688 · fetched Nov 12, 2026
- A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMMLPHASE1_PHASE2 · TERMINATED · started Feb 25, 2025ClinicalTrials.gov NCT06563804 · fetched Nov 12, 2026
- Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 MutationPHASE3 · RECRUITING · started Dec 3, 2024ClinicalTrials.gov NCT06465953 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 31, 2024ClinicalTrials.gov NCT06116136 · fetched Nov 12, 2026
- Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 7, 2024ClinicalTrials.gov NCT06162572 · fetched Nov 12, 2026
- Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment RegimensPHASE3 · RECRUITING · started Jul 9, 2024ClinicalTrials.gov NCT06127407 · fetched Nov 12, 2026
- S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 29, 2024ClinicalTrials.gov NCT06188702 · fetched Nov 12, 2026
- Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaPHASE1_PHASE2 · TERMINATED · started Oct 23, 2023ClinicalTrials.gov NCT05921760 · fetched Nov 12, 2026
- A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy SubjectsPHASE1 · COMPLETED · started Apr 14, 2023ClinicalTrials.gov NCT05843708 · fetched Nov 12, 2026
- A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid TumorsPHASE1_PHASE2 · TERMINATED · started Sep 8, 2021ClinicalTrials.gov NCT05159388 · fetched Nov 12, 2026